EICHORCondition: Urinary Bladder Diseases · Urinary Bladder Overactive · Urologic Diseases · Sponsor: Astellas Pharma Europe Ltd.
The purpose of this study was to see if adding a new type of medication recently approved to treat overactive bladder (mirabegron) to an antimuscarinic treatment (solifenacin) would be more effective in controlling incontinence than when using the antimuscarinic treatment alone.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Genova Clinical Research | Tucson, Arizona, United States | — |
| Associated Pharmaceutical Research Center, Inc. | Buena Park, California, United States | — |
| The American Institute of Research | Los Angeles, California, United States | — |
| Bayview Research Group | Valley Village, California, United States | — |
| Meridien Research | Brooksville, Florida, United States | — |
| Innovative Research of West FL | Clearwater, Florida, United States | — |
| Best Quality Research Inc. | Hialeah, Florida, United States | — |
| Palmetto Professional Research | Hialeah, Florida, United States | — |
| Urology Center of Central Florida | Kissimmee, Florida, United States | — |
| Meridien Research | Tampa, Florida, United States | — |
| Stedman Clinical Trials | Tampa, Florida, United States | — |
| Private Practice | West Palm Beach, Florida, United States | — |
+ 207 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT01908829